CA3107370A1 - Methods of treatment and prevention of alzheimer's disease - Google Patents
Methods of treatment and prevention of alzheimer's disease Download PDFInfo
- Publication number
- CA3107370A1 CA3107370A1 CA3107370A CA3107370A CA3107370A1 CA 3107370 A1 CA3107370 A1 CA 3107370A1 CA 3107370 A CA3107370 A CA 3107370A CA 3107370 A CA3107370 A CA 3107370A CA 3107370 A1 CA3107370 A1 CA 3107370A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- months
- administration
- composition
- relative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702659P | 2018-07-24 | 2018-07-24 | |
| US62/702,659 | 2018-07-24 | ||
| US201862749614P | 2018-10-23 | 2018-10-23 | |
| US62/749,614 | 2018-10-23 | ||
| US201962824162P | 2019-03-26 | 2019-03-26 | |
| US62/824,162 | 2019-03-26 | ||
| US201962846902P | 2019-05-13 | 2019-05-13 | |
| US62/846,902 | 2019-05-13 | ||
| US201962874684P | 2019-07-16 | 2019-07-16 | |
| US62/874,684 | 2019-07-16 | ||
| PCT/US2019/043067 WO2020023530A2 (en) | 2018-07-24 | 2019-07-23 | Methods of treatment and prevention of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3107370A1 true CA3107370A1 (en) | 2020-01-30 |
Family
ID=67551415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3107370A Pending CA3107370A1 (en) | 2018-07-24 | 2019-07-23 | Methods of treatment and prevention of alzheimer's disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210324056A1 (enExample) |
| EP (1) | EP3826674A2 (enExample) |
| JP (2) | JP7541505B2 (enExample) |
| KR (1) | KR20210039402A (enExample) |
| CN (2) | CN112805031A (enExample) |
| AU (1) | AU2019309938A1 (enExample) |
| BR (1) | BR112021001272A2 (enExample) |
| CA (1) | CA3107370A1 (enExample) |
| IL (3) | IL280315B2 (enExample) |
| MX (1) | MX2021000778A (enExample) |
| PH (1) | PH12021500006A1 (enExample) |
| TW (1) | TW202019471A (enExample) |
| WO (1) | WO2020023530A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND USES THEREOF |
| HRP20251087T1 (hr) * | 2020-03-20 | 2025-11-07 | Eisai R&D Management Co., Ltd. | Formulacije visoke koncentracije anti-amiloidnih beta peptidnih protofibrilnih protutijela i postupci njihove upotrebe |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| US20230302009A1 (en) * | 2020-08-12 | 2023-09-28 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| WO2023111618A1 (en) * | 2021-12-17 | 2023-06-22 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| AU2022410770A1 (en) * | 2021-12-17 | 2024-06-13 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| AU2022439338A1 (en) * | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RS51723B2 (sr) * | 2006-03-23 | 2018-03-30 | Bioarctic Neuroscience Ab | Poboljšana antitela selektivna za protofibrile i njihova primena |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| US20100317850A1 (en) | 2008-01-18 | 2010-12-16 | Yuichi Suzuki | Condensed aminodihydrothiazine derivative |
| PL2448968T3 (pl) | 2009-06-29 | 2021-09-13 | Bioarctic Ab | Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta |
| JP2013521233A (ja) * | 2010-02-25 | 2013-06-10 | ヤンセン アルツハイマー イミュノセラピー | Ａβを標的とする免疫療法のＰＥＴモニタリング |
| CN102869680B (zh) | 2010-02-26 | 2016-10-05 | 生命北极神经科学公司 | 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用 |
| SG191710A1 (en) | 2011-01-21 | 2013-08-30 | Eisai R&D Man Co Ltd | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
| PE20170768A1 (es) | 2014-07-10 | 2017-07-04 | Eisai Randd Man Co Ltd | Anticuerpos de union a protofibrillas ab mejorados |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN114019170A (zh) * | 2016-01-20 | 2022-02-08 | 基因泰克公司 | 用于阿尔茨海默氏病的高剂量治疗 |
| EP3454904B1 (en) * | 2016-05-13 | 2022-12-14 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| AU2017347838B2 (en) * | 2016-10-27 | 2023-04-27 | Eisai R&D Management Co., Ltd. | Composition comprising an anti-Αβ protofibril antibody and a beta-secretase BACE1 inhibitor for the treatment of Alzheimer's disease |
-
2019
- 2019-07-23 IL IL280315A patent/IL280315B2/en unknown
- 2019-07-23 MX MX2021000778A patent/MX2021000778A/es unknown
- 2019-07-23 US US17/250,448 patent/US20210324056A1/en active Pending
- 2019-07-23 AU AU2019309938A patent/AU2019309938A1/en active Pending
- 2019-07-23 JP JP2021503770A patent/JP7541505B2/ja active Active
- 2019-07-23 BR BR112021001272-9A patent/BR112021001272A2/pt unknown
- 2019-07-23 WO PCT/US2019/043067 patent/WO2020023530A2/en not_active Ceased
- 2019-07-23 EP EP19750196.8A patent/EP3826674A2/en active Pending
- 2019-07-23 CN CN201980062781.8A patent/CN112805031A/zh active Pending
- 2019-07-23 CN CN202411217698.2A patent/CN118924896A/zh active Pending
- 2019-07-23 KR KR1020217005322A patent/KR20210039402A/ko not_active Ceased
- 2019-07-23 CA CA3107370A patent/CA3107370A1/en active Pending
- 2019-07-24 TW TW108126224A patent/TW202019471A/zh unknown
-
2021
- 2021-01-21 PH PH12021500006A patent/PH12021500006A1/en unknown
-
2024
- 2024-01-14 IL IL310132A patent/IL310132B1/en unknown
- 2024-05-10 JP JP2024077300A patent/JP2024112859A/ja active Pending
-
2025
- 2025-09-25 IL IL323583A patent/IL323583A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL280315B1 (en) | 2024-02-01 |
| BR112021001272A2 (pt) | 2021-04-27 |
| CN118924896A (zh) | 2024-11-12 |
| EP3826674A2 (en) | 2021-06-02 |
| IL310132B1 (en) | 2025-11-01 |
| MX2021000778A (es) | 2021-03-31 |
| IL323583A (en) | 2025-11-01 |
| IL280315B2 (en) | 2024-06-01 |
| IL310132A (en) | 2024-03-01 |
| JP7541505B2 (ja) | 2024-08-28 |
| JP2024112859A (ja) | 2024-08-21 |
| JP2021532126A (ja) | 2021-11-25 |
| CN112805031A (zh) | 2021-05-14 |
| WO2020023530A2 (en) | 2020-01-30 |
| KR20210039402A (ko) | 2021-04-09 |
| PH12021500006A1 (en) | 2021-09-13 |
| WO2020023530A3 (en) | 2020-03-12 |
| IL280315A (en) | 2021-03-25 |
| AU2019309938A1 (en) | 2021-03-11 |
| US20210324056A1 (en) | 2021-10-21 |
| TW202019471A (zh) | 2020-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3107370A1 (en) | Methods of treatment and prevention of alzheimer's disease | |
| JP2018111723A (ja) | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 | |
| JP2017160178A (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| US20250163135A1 (en) | Biomarkers for alzheimer's disease treatment | |
| CN117244056A (zh) | 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物 | |
| US20250377367A1 (en) | Methods of treatment using p-tau181 level | |
| US20240352109A1 (en) | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof | |
| JP5954916B1 (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| RU2832167C2 (ru) | Способы лечения и предупреждения болезни альцгеймера | |
| EP4626918A1 (en) | Methods of treatment using a tau pet level | |
| CN117999094A (zh) | 抗Aβ初原纤维抗体的皮下配制品及其使用方法 | |
| BR122025003268A2 (pt) | Métodos de tratamento e prevenção de doença de alzheimer | |
| TW202518027A (zh) | 抗微生物肽 | |
| TW202513583A (zh) | 使用抗Ａβ初原纖維抗體之治療方法 | |
| AU2024286486A1 (en) | Methods of treatment using an anti-abeta protofibril antibody |